ReviewGynecologic oncology reports2019
Review in Gynecologic oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06304922 (BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary), which is not on this map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Efficacy and safety of PARP inhibitors monotherapy or combination therapy with anti-angiogenics in ovarian cancer: a network meta-analysis.Frontiers in oncology · 2025Pooled it
- The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- The P7 peptide antagonizes bFGF-induced malignant behaviors of ovarian cancer by inhibiting MEK/ERK signaling pathway.Future science OA · 2026Article
- Exploring willingness to pay out-of-pocket for genetic testing among ovarian cancer patients in Malaysia, a middle-income country in Asia.Journal of gynecologic oncology · 2026Observational
- Current evidence and emerging approaches in immunotherapy for gynecological cancers.Discover oncology · 2026Review
- High-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions.International journal of molecular sciences · 2026Review
- Prevalence of BRCA1/2 Mutation in High-Grade Non-Mucinous Ovarian Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2025Observational
- Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer.The oncologist · 2025Review
- Review
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024Article
- The Role of Tumor Biomarkers in Tailoring the Approach to Advanced Ovarian Cancer.International journal of molecular sciences · 2024Review
- The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Tumors.Cancer research · 2024Article
- Endometriosis-Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance.International journal of molecular sciences · 2024Review
- Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance.Frontiers in oncology · 2024Article
- The impact of pathogenicSAGE open medicine · 2024Article
- MicroRNAs as Potential Biomarkers in Gynecological Cancers.Biomedicines · 2023Review
- Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon.Gynecologic oncology reports · 2023Article
- Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention.Biomolecules · 2023Review
- Potential prognostic role of somatic mutations in a set of cancer susceptibility genes in ovarian carcinoma: A follow-up multicentric study from Pakistan.Cancer biomarkers : section A of Disease markers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify the frequency of
methodsPatients with EOC included fallopian tube cancer or peritoneal cancer with high grade serous or high grade endometrioid were recruited.
resultsA total of 87 patients were recruited; majority of them (88.5%) were EOC, 5.7% fallopian tube cancer, 4.6% peritoneal cancer, and 1.1% synchronous primary ovarian and endometrial cancer. Seventy-four patients (85.1%) had high grade serous carcinoma and 13 patients (14.9%) had high grade endometrioid carcinoma. Germline
conclusionThe frequency of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.